Google
HIND — VYOME HOLDINGS, INC. (Healthcare >> Biotechnology)
HIND FAQ
What is HIND's ROE?
VYOME HOLDINGS, INC. reports a Return on Equity (ROE) of -196.50%.
What is HIND's dividend yield?
VYOME HOLDINGS, INC. offers a dividend yield of 0.00%.
What is HIND's Deepscope Quality Score?
Deepscope rates HIND's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HIND?
Deepscope's AI Timing Score for HIND is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does HIND belong to?
VYOME HOLDINGS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.18
Price
0.11
(4.83%)
Day Change
|
|
|---|
HIND, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.18 |
| PBV / Sector |
1.84 / 4.79
|
| Earning Per Share | -1.95 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
0.06 M
GREAT
|
| Average 1W Daily Value |
0.05 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-11 09:55:08 |
| Symbol | HIND |
| Name | VYOME HOLDINGS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 7.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 14.81 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Harvard Square, Cambridge, MA, United States, 02138
Phone: 973-832-8147
Website: https://www.vyometx.com
Sector: Healthcare >> Biotechnology
Description: Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
